


## Cyclo(RGDyK) trifluoroacetate

Cat. No.:	HY-100563
CAS No.:	250612-42-1
Molecular Formula:	C <sub>31</sub> H <sub>43</sub> F <sub>6</sub> N <sub>9</sub> O <sub>12</sub>
Molecular Weight:	847.72
Sequence Shortening:	RGDYK
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Sealed storage, away from moisture
	Powder    -80°C    2 years
	-20°C    1 year



\* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 130 mg/mL (153.35 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.1796 mL	5.8982 mL	11.7963 mL
	5 mM	0.2359 mL	1.1796 mL	2.3593 mL
	10 mM	0.1180 mL	0.5898 mL	1.1796 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.17 mg/mL (2.56 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.17 mg/mL (2.56 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: 2.17 mg/mL (2.56 mM); Clear solution; Need warming

### BIOLOGICAL ACTIVITY

#### Description

Cyclo(RGDyK) trifluoroacetate is a potent and selective α<sub>v</sub>β<sub>3</sub> integrin inhibitor with an IC<sub>50</sub> of 20 nM.

#### IC<sub>50</sub> & Target

α<sub>v</sub>β<sub>3</sub>  
20 nM (IC<sub>50</sub>)

## In Vitro

Cyclo(RGDyK) (c(RGDyK(SAA)) shows high affinity and selectivity for  $\alpha_V\beta_3$  over  $\alpha_V\beta_5$  ( $IC_{50}=4000$  nM) and  $\alpha_{IIb}\beta_3$  ( $IC_{50}=3000$  nM) [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Stem Cell Res Ther. 2022 Jul 18;13(1):327.
- Pharmaceuticals. 2021 Mar 14;14(3):260.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Haubner R, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001 Feb;42(2):326-36.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA